Boothbay Fund Management’s Bicycle Therapeutics BCYC Stock Holding History

Boothbay Fund Management’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-42,133	Closed	-$1.08M	–	1736
2023 Q2	$1.08M	Sell	42,133 -846	-2%	-$19.6K	0.02%	800
2023 Q1	$914K	Buy	+42,979	New	+$1.08M	0.02%	1031
2022 Q2	–	Sell	-46,770	Closed	-$2.05M	–	2254
2022 Q1	$2.05M	Sell	46,770 -16,646	-26%	-$777K	0.05%	573
2021 Q4	$3.86M	Buy	63,416 +8,510	+15%	+$470K	0.09%	266
2021 Q3	$2.28M	Buy	+54,906	New	+$1.92M	0.06%	401

Other funds holding BCYC

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Boothbay Fund Management's BCYC Position: Q3 2023 in Review

Boothbay Fund Management sold out of Bicycle Therapeutics (BCYC) in Q3 2023, closing a stake of 42,133 shares — an estimated $1.08M sold.

Boothbay Fund Management first reported a position in BCYC in Q3 2021 and held it in 5 quarters. The position peaked at $3.86M in Q4 2021. 101 funds tracked by Wall St. Rank hold BCYC as of Q3 2023.

Boothbay Fund Management reported no remaining Bicycle Therapeutics position as of Q3 2023 after selling out during the quarter.
Boothbay Fund Management sold 42,133 Bicycle Therapeutics shares in Q3 2023, an estimated $1.08M.
Boothbay Fund Management first reported a position in Bicycle Therapeutics in Q3 2021 and held it in 5 quarters.
Boothbay Fund Management's Bicycle Therapeutics position peaked at $3.86M in Q4 2021.
101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2023.

Based on Boothbay Fund Management's 13F filing for Q3 2023, filed 14 Nov 2023.